Quercetin abrogates chemoresistance in melanoma cells by modulating ΔNp73

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Thangasamy, Thilakavathy ^a   Sittadjody, Sivanandane ^a   Mitchell, Geoffrey C ^a   Mendoza, Erin E ^a   Radhakrishnan, Vijayababu M ^b   Limesand, Kirsten H ^a   Burd, Randy ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROTEIN P53; PROTEIN P73; QUERCETIN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; ATM PROTEIN; CELL CYCLE PROTEIN; DACARBAZINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; MELANIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIZATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MELANOMA CELL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STAINING; BIOSYNTHESIS; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; GENETICS; MELANOMA; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; RNA INTERFERENCE; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DACARBAZINE; DNA DAMAGE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANINS; MELANOMA; MUTATION; NUCLEAR PROTEINS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; QUERCETIN; RNA INTERFERENCE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77953296031     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-282     Document Type: Article

References (38)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-7. 10.1038/nature05661, 17314971.
2. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009, 4:551-579. 10.1146/annurev.pathol.3.121806.151541, 19400696.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26. 10.3322/canjclin.53.1.5, 12568441.
4. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745. 10.1200/JCO.2006.06.0483, 16966688.
5. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61. 10.1016/S0305-7372(97)90019-0, 9189180.
6. Tentori L, Graziani G. Recent approaches to improve the antitumor efficacy of temozolomide. Curr Med Chem 2009, 16:245-257. 10.2174/092986709787002718, 19149575.
7. Metodiewa D, Jaiswal AK, Cenas N, Dickancaite E, Segura-Aguilar J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med 1999, 26:107-116. 10.1016/S0891-5849(98)00167-1, 9890646.
8. Simonova M, Wall A, Weissleder R, Bogdanov A. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res 2000, 60:6656-6662.
9. Larocca LM, Teofili L, Maggiano N, Piantelli M, Ranelletti FO, Leone G. Quercetin and the growth of leukemic progenitors. Leuk Lymphoma 1996, 23:49-53. 10.3109/10428199609054801, 9021685.
10. Elangovan V, Sekar N, Govindasamy S. Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesis. Cancer Lett 1994, 87:107-113. 10.1016/0304-3835(94)90416-2, 7954363.
11. Thangasamy T, Sittadjody S, Lanza-Jacoby S, Wachsberger P, Limesand K, Burd R. Quercetin Selectively Inhibits Bioreduction and Enhances Apoptosis in Melanoma Cells that Overexpress Tyrosinase. Nutrition and cancer 2007, 59:1-11.
12. Thangasamy T, Sittadjody S, Limesand KH, Burd R. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol 2008, 30:371-387.
13. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151. 10.1038/sj.onc.1206454, 12789290.
14. Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 2008, 21:525-533. 10.1111/j.1755-148X.2008.00495.x, 18761658.
15. Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci 2005, 96:729-737. 10.1111/j.1349-7006.2005.00116.x, 16271066.
16. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004, 2:371-386.
17. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002, 1:617-628.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-8. 10.1006/meth.2001.1262, 11846609.
19. Limesand KH, Schwertfeger KL, Anderson SM. MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells. Mol Cell Biol 2006, 26:8840-56. 10.1128/MCB.01846-05, 1636839, 16982679.
20. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004, 10:626-633. 10.1158/1078-0432.CCR-0153-03, 14760085.
21. Tomkova K, Belkhiri A, El-Rifai W, Zaika AI. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res 2004, 64:6390-6393. 10.1158/0008-5472.CAN-04-2176, 15374945.
22. Melino G, De L, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002, 2:605-615. 10.1038/nrc861, 12154353.
23. DeYoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007, 26:5169-5183. 10.1038/sj.onc.1210337, 17334395.
24. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M, Kaina B. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009, 100:322-333. 10.1038/sj.bjc.6604856, 19127257.
25. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007, 26:186-97. 10.1038/sj.onc.1209785, 16819506.
26. Kaina B, Haas S, Kappes H. A general role for c-Fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res 1997, 57:2721-2731.
27. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007, 6:1079-1099. 10.1016/j.dnarep.2007.03.008, 17485253.
28. Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P. Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer 2007, 97:1225-1233. 10.1038/sj.bjc.6604017, 2360470, 17968428.
29. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M, Kaina B. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009, 100:322-333. 10.1038/sj.bjc.6604856, 19127257.
30. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M, Kaina B. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 2009, 100:322-333. 10.1038/sj.bjc.6604856, 2634706, 19127257.
31. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002, 18:90-95. 10.1016/S0168-9525(02)02595-7, 11818141.
32. Muller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 2005, 12:1564-1577. 10.1038/sj.cdd.4401774, 16195739.
33. Di VA, Sessa F, Casciano I, Banelli B, Franzi F, Brigati C, Allemanni G, Russo P, Dominioni L, Romani M. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. Int J Oncol 2009, 34:449-456.
34. Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mossner J, Engeland K, Wittekind C. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999, 91:1154-1158. 10.1093/jnci/91.13.1154, 10393724.
35. Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mossner J, Wittekind C. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 1999, 80:1069-1074. 10.1038/sj.bjc.6690465, 2363034, 10362118.
36. Douc-Rasy S, Barrois M, Echeynne M, Kaghad M, Blanc E, Raguenez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D, Benard J. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol 2002, 160:631-639. 1850642, 11839584.
37. Inoue T, Stuart J, Leno R, Maki CG. Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 2002, 277:15053-15060. 10.1074/jbc.M200248200, 11847229.
38. Quelo I, Gauthier C, St-Arnaud R. Casein kinase II phosphorylation regulates alphaNAC subcellular localization and transcriptional coactivating activity. Gene Expr 2005, 12:151-163. 10.3727/000000005783992070, 16128000.